Clinical Trial Update: To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study to assess whether repeat dosing of darapladib alters the pharmacokinetics of rosuvastatin and to evaluate safety/tolerability in healthy volunteer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• CRESTOR (Rosuvastatin)
• Darapladib (darapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 1 | Status: COMPLETED